Biomea Fusion, Inc. (BMEA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DP Drew Phillips Fortitude Family Office LLC | 454 | $793.93 | $544.8 | -$249.13 | -31.38% |
| BFG Birch Financial Group LLC Birch Financial Group LLC | 14,000 | $25,200 | $16,800 | -$8,400 | -33.33% |
Biomea Fusion, Inc. (BMEA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biomea Fusion, Inc. ever had a stock split?
Biomea Fusion, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael J. Hitchcock CEO | NASDAQ (NGS) Exchange | 09077A106 CUSIP |
| US Country | 79 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Biomea Fusion, Inc. is a forward-thinking clinical-stage biopharmaceutical firm with a dedicated mission to pioneer the development of covalent small molecule drugs. With an emphasis on addressing genetically defined cancers and metabolic diseases, the company leverages cutting-edge science and research to break new ground in the medical field. Founded in 2017 and located in Redwood City, California, Biomea Fusion, Inc. represents a vibrant and innovative presence in the biopharmaceutical landscape, aiming to transform the treatment paradigms for patients suffering from serious health conditions.
Products and Services
BMF-219: Positioned as the flagship product in Biomea Fusion’s pipeline, BMF-219 marks a significant advancement in the treatment of both oncological and metabolic conditions. This covalent inhibitor of menin is specifically engineered for the management of liquid and solid tumors, providing a new hope for cancer patients. Beyond its application in oncology, BMF-219 is under investigation for its potential in addressing type 2 diabetes, showcasing the versatility and innovative approach of Biomea Fusion in leveraging its technology platform to meet diverse healthcare needs.
